Аннотация:
At the first phase of the research the evaluation of the activity of cytochrome CYP2C9 in 18 elderly and geriatric patients was carried out, mean age of the patients was 71.6±9.6 years. At the second phase the efficiency and safety of losartan trial in 18 healthy volunteers of the first period of mature age 26.3±3.5 years was evaluated. To evaluate the activity of isoenzyme of cytochrome P450 CYP2C9 the determination of the concentration of active metabolite of Losartan E-3174 in the urine to the concentration of losartan was used. The concentration ratio E-3174 to losartan in elderly and senile patients was 1.84±0.15, in healthy young volunteers - 3.28±0.77. A statistically significant metabolic E-3174/losartan ratio decrease in elderly and senile patients was demonstrated, which indicates about the decreased activity of CYP2C9 in that age group. © Group of authors, 2017.
Sy'chev D. A. Dmitrij Alekseevich 1975-
Bordovsky S. P.
Nikulin V. E`. Vladislav E`duardovich 1994-
Pol`shina N. I. Natal`ya Ivanovna 1994-
Anikin G. S. Georgij Stanislavovich 1983-
Danilina K. S. Kristina Sergeevna 1990-
Smirnov V. V. Valerij Valeryevich 1985-
Сычев Д. А. Дмитрий Алексеевич 1975-
Бордовскy С. П.
Никулин В. Э. Владислав Эдуардович 1994-
Польшина Н. И. Наталья Ивановна 1994-
Аникин Г. С. Георгий Станиславович 1983-
Данилина К. С. Кристина Сергеевна 1990-
Смирнов В. В. Валерий Валерьевич 1985-
Comparative analysis of activity of cytochrome isoenzyme P450 CYP2C9 in elderly and senile patients and with that in healthy volunteers of the first period of middle age
Comparative analysis of activity of cytochrome isoenzyme P450 CYP2C9 in elderly and senile patients and with that in healthy volunteers of the...
Текст визуальный непосредственный
Медицинский вестник Северного Кавказа
Ставропольский государственный медицинский университет
Vol.12, Issue3 P. 250-253
2017
Статья
CYP2C9 isoform Drug side effects Drug therapy Elderly people Losartan
At the first phase of the research the evaluation of the activity of cytochrome CYP2C9 in 18 elderly and geriatric patients was carried out, mean age of the patients was 71.6±9.6 years. At the second phase the efficiency and safety of losartan trial in 18 healthy volunteers of the first period of mature age 26.3±3.5 years was evaluated. To evaluate the activity of isoenzyme of cytochrome P450 CYP2C9 the determination of the concentration of active metabolite of Losartan E-3174 in the urine to the concentration of losartan was used. The concentration ratio E-3174 to losartan in elderly and senile patients was 1.84±0.15, in healthy young volunteers - 3.28±0.77. A statistically significant metabolic E-3174/losartan ratio decrease in elderly and senile patients was demonstrated, which indicates about the decreased activity of CYP2C9 in that age group. © Group of authors, 2017.